Table 2.
Prevalence of drug resistance according to region
| All (N = 1568)a | North (N = 265) | Northeast (N = 265) | South (N = 273)a | Southeast (N = 500) | Central‐West (N = 265) | |
|---|---|---|---|---|---|---|
| NRTI | 57 (3.6;2.8 to 4.7) | 13 (4.9; 2.7 to 8.4) | 11 (4.1; 2.2 to 7.5) | 5 (1.8; 0.7 to 4.5) | 20 (4; 2.5 to 6.2) | 8 (3; 1.4 to 6.1) |
| NNRTI | 91 (5.8; 4.7 to 7.1) | 14 (5.3; 3 to 8.9) | 12 (4.5; 2.5 to 8) | 19 (7; 4.3 to 10.8) | 34 (6.8; 4.8 to 9.5) | 12 (4.5; 2.5 to 8) |
| NRTI/NNRTI | 131 (8.3; 7 to 10) | 24 (9; 6 to 13.3) | 21 (7.9; 5.1 to 12) | 21 (7.7; 4.9 to 11.7) | 49 (9.8; 7.4 to 12.8) | 16 (6; 3.6 to 9.8) |
| PIb | 25 (1.6; 1 to 2.4) | 6 (2.2; 0.9 to 5.1) | 6 (2.2; 0.9 to 5.1) | 3 (1.1; 0.3 to 3.4) | 9 (1.8; 0.9 to 3.5) | 1 (0.4; 0.02 to 2.4) |
| Any resistance | 150 (9.5; 8.2 to 11.1) | 27 (10.2; 6.9 to 14.6) | 25 (9.4; 6.3 to 13.8) | 24 (8.8; 5.8 to 12.9) | 56 (11.2; 8.6 to 14.4) | 18 (6.8; 4.2 to 10.7) |
Results are presented as N (%; 95% CI). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non‐nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a
p < 0.01 for comparisons between prevalence of resistance to NNRTI and NRTIs.
b
p < 0.01 for comparisons between prevalence of resistance to PIs and NRTI/NNRTI in the entire sample (All) and in each region separately.